Bicycle Therapeutics Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Public

  • Employees
  • 284

Employees

  • Stock Symbol
  • 50BA

Stock Symbol

  • Share Price
  • $12.45
  • (As of Friday Closing)

Bicycle Therapeutics General Information

Description

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Blocks A & B Portway Building
  • Granta Park, Great Abington
  • Cambridge CB21 6GS
  • England, United Kingdom
+44 01223
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
BER
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Blocks A & B Portway Building
  • Granta Park, Great Abington
  • Cambridge CB21 6GS
  • England, United Kingdom
+44 01223

Bicycle Therapeutics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bicycle Therapeutics Stock Performance

As of 14-Feb-2025, Bicycle Therapeutics’s stock price is $12.45. Its current market cap is $867M with 69M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$12.45 $12.37 $11.23 - $28.73 $867M 69M 0.82 -$3.31

Bicycle Therapeutics Financials Summary

As of 30-Sep-2024, Bicycle Therapeutics has a trailing 12-month revenue of $36.9M.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 642,695 240,584 561,379 1,563,110
Revenue 36,898 26,976 14,463 11,697
EBITDA (190,274) (183,400) (112,964) (64,209)
Net Income (166,276) (180,664) (112,717) (66,819)
Total Assets 996,746 595,344 410,609 479,792
Total Debt 11,087 44,956 44,325 44,337
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Bicycle Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Bicycle Therapeutics‘s full profile, request access.

Request a free trial

Bicycle Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Bicycle Therapeutics‘s full profile, request access.

Request a free trial

Bicycle Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are r
Drug Discovery
Cambridge, United Kingdom
284 As of 2023

South San Francisco, CA
 

Austin, TX
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bicycle Therapeutics Competitors (47)

One of Bicycle Therapeutics’s 47 competitors is CytomX Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Rein Therapeutics Formerly VC-backed Austin, TX
Rhythm Pharmaceuticals Formerly VC-backed Boston, MA
Cyclenium Pharma Corporate Backed or Acquired Montreal, Canada
Protagonist Therapeutics Formerly VC-backed Newark, CA
You’re viewing 5 of 47 competitors. Get the full list »

Bicycle Therapeutics Patents

Bicycle Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201715621-D0 Bicycle peptide ligands specific for epha2 Inactive 27-Sep-2017
GB-201715239-D0 Interaction with multiple sites Inactive 21-Sep-2017
GB-201713559-D0 Modification of polypeptides Inactive 23-Aug-2017
GB-201713561-D0 Peptide derivatives having novel linkage structures Inactive 23-Aug-2017
GB-201713560-D0 Peptide ligands for binding to mt1-mmp Inactive 23-Aug-2017
To view Bicycle Therapeutics’s complete patent history, request access »

Bicycle Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bicycle Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Bicycle Therapeutics‘s full profile, request access.

Request a free trial

Bicycle Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 28, 2024

15.83 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,120

Rank

Percentile

Pharmaceuticals

Industry

of 853

Rank

Percentile

Biotechnology

Subindustry

of 368

Rank

Percentile

To view Bicycle Therapeutics’s complete esg history, request access »

Bicycle Therapeutics FAQs

  • When was Bicycle Therapeutics founded?

    Bicycle Therapeutics was founded in 2009.

  • Where is Bicycle Therapeutics headquartered?

    Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.

  • What is the size of Bicycle Therapeutics?

    Bicycle Therapeutics has 284 total employees.

  • What industry is Bicycle Therapeutics in?

    Bicycle Therapeutics’s primary industry is Drug Discovery.

  • Is Bicycle Therapeutics a private or public company?

    Bicycle Therapeutics is a Public company.

  • What is Bicycle Therapeutics’s stock symbol?

    The ticker symbol for Bicycle Therapeutics is 50BA.

  • What is the current stock price of Bicycle Therapeutics?

    As of 14-Feb-2025 the stock price of Bicycle Therapeutics is $12.45.

  • What is the current market cap of Bicycle Therapeutics?

    The current market capitalization of Bicycle Therapeutics is $867M.

  • What is Bicycle Therapeutics’s current revenue?

    The trailing twelve month revenue for Bicycle Therapeutics is $36.9M.

  • Who are Bicycle Therapeutics’s competitors?

    CytomX Therapeutics, Rein Therapeutics, Rhythm Pharmaceuticals, Cyclenium Pharma, and Protagonist Therapeutics are some of the 47 competitors of Bicycle Therapeutics.

  • What is Bicycle Therapeutics’s annual earnings per share (EPS)?

    Bicycle Therapeutics’s EPS for 12 months was -$3.31.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »